At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
1.5 mg or 2.0 mg CJC-1134-PC +1 moredrug
Likely dose
1.5 mg or 2.0 mg CJC-1134-PCfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Twice-a-week Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy
In Brief
A Phase 2 clinical trial evaluating 1.5 mg or 2.0 mg CJC-1134-PC and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 90 participants across 1 site.
Detailed Summary
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients who are currently on metformin monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMay 2008
Primary CompletionNov 2008
TodayJul 2026
First PostedMay 7, 2008
Enrollment StartMar 1, 2008
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.2 years ago
Interventions
1.5 mg or 2.0 mg CJC-1134-PCdrug
twice-a-week
Placebodrug
twice-a-week